JP7534729B2 - SARS coronavirus 2 inactivator - Google Patents

Description

The present invention relates to a SARS coronavirus 2 inactivating agent, a composition for inactivating SARS coronavirus 2, and a method for inactivating SARS coronavirus 2.

Washing hands and hard surfaces in the living environment is considered to be one of the important preventive methods for viral infections such as influenza and colds. In recent years, the spread of infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has also become a serious problem. Unlike bacteria, pathogenic viruses are not capable of self-replication, but instead parasitize the cells of animals such as humans or bacteria, and reproduce by utilizing the functions of those cells. Therefore, there are few effective antiviral drugs for post-infection use, such as antibiotics for bacteria, and it is effective to prevent infection by using disinfectants, etc.

As an approach from this perspective, it is believed that inactivating viruses is useful for preventing viral infections. It has been known that anionic surfactants such as sodium dodecyl sulfate have the ability to inactivate viruses. However, this effect can only be achieved under conditions such as contact with a solution with a high concentration of anionic surfactant for 30 minutes or more. There is a strong demand for technology that can achieve high virus inactivation ability in a short period of time, such as when washing hands, and in a solution with a low concentration of anionic surfactant from the perspective of environmental safety.

Patent Document 1 describes a virus inactivating agent containing di(2-ethylhexyl)sulfosuccinate.
Patent Document 2 discloses a technique in which a sulfosuccinic acid surfactant is used as an auxiliary component of a virus inactivating agent.

Japanese Unexamined Patent Publication No. 62-500524 Japanese Patent Application Publication No. 58-135802

However, as shown in Table 8 of Patent Document 1, even when a solution of di(2-ethylhexyl)sulfosuccinate having a concentration of 0.01 mg/ml is brought into contact with viruses for 1 hour, the virus inactivation ability is only 19%, which is not a fully satisfactory level. Furthermore, Patent Documents 1 and 2 do not suggest or even suggest that a sulfosuccinate having a specific alkyl group can remove viruses at a low concentration in a short period of time.
The present invention particularly provides a SARS-coronavirus 2 inactivating agent, a composition for inactivating SARS-coronavirus 2, and a method for inactivating SARS-coronavirus 2, which have a high inactivation effect on SARS-coronavirus 2 even at a low concentration.

The present invention relates to a SARS coronavirus 2 inactivator that contains, as an active ingredient, (a) a sulfosuccinic acid branched alkyl ester having a branched alkyl group having from 9 to 12 carbon atoms or a salt thereof [hereinafter referred to as component (a)].

The present invention also relates to a composition for inactivating SARS coronavirus 2, which contains component (a) as an active ingredient and also contains water.

The present invention also relates to a method for inactivating SARS-coronavirus 2, which comprises contacting the SARS-coronavirus 2 inactivation composition of the present invention with a target surface on which SARS-coronavirus 2 is present.

The present invention provides a SARS-coronavirus 2 inactivating agent, a composition for inactivating SARS-coronavirus 2, and a method for inactivating SARS-coronavirus 2, which have a high inactivation effect against SARS-coronavirus 2 even at low concentrations.

In the present invention, the SARS coronavirus 2 inactivation effect is verified using a system in which SARS-CoV-2 that has been brought into contact with an evaluation sample is infected into Vero C1008 cells. Specifically, the verification is based on the judgment of the inactivation verification test described in the [Anti-SARS-CoV-2 verification test using Vero C1008] described in the Examples.

[SARS coronavirus 2 inactivator]
<Component (a)>
The component (a) of the present invention is a branched alkyl sulfosuccinate ester having a branched alkyl group having from 9 to 12 carbon atoms, or a salt thereof.
The component (a) may be a monoester or a diester, and is preferably a branched alkyl sulfosuccinate diester in which the branched alkyl group has 9 to 12 carbon atoms.

The branched alkyl group of component (a) is preferably a branched alkyl group having 9 or 10 carbon atoms, and more preferably a branched alkyl group having a main chain having 6 or 7 carbon atoms and one or more side chains, the total number of carbon atoms in the side chains being 3.
The branched alkyl group of component (a) is preferably a branched alkyl group selected from a 2-propylheptyl group and a 3,5,5-trimethylhexyl group.

Component (a) includes a branched sulfosuccinic acid ester represented by the following general formula (a1):

[In the formula, R ^1a and R ^2a each independently represent a branched alkyl group having 9 to 12 carbon atoms. A ¹ and A ² each independently represent an alkylene group having 2 to 4 carbon atoms. x and y each independently represent the average number of moles added and each independently represent 0 to 6. M ¹ represents a hydrogen atom or a cation.]

Further examples of component (a) include branched alkyl sulfosuccinate esters represented by the following general formula (a1-1). This compound is a compound in which x = 0 and y = 0 in general formula (a1).

[In the formula, R ^1a and R ^2a each independently represent a branched alkyl group having 9 to 12 carbon atoms. M ¹ represents a hydrogen atom or a cation.]

The following explanation can be applied to both general formula (a1) and general formula (a1-1).
The carbon numbers of R ^1a and R ^2a may be the same or different.
In the present invention, the branched chain hydrocarbon group includes a hydrocarbon residue obtained by removing a hydroxyl group from a secondary alcohol.

In the present invention, among the branched chain hydrocarbon groups of R ^1a and R ^2a , the hydrocarbon chain having the largest number of carbon atoms counted from the carbon atom bonded to the oxygen atom is the main chain, and the hydrocarbon chain branched and bonded to the main chain is the side chain.
When two or more main chains are considered, that is, when there are two or more hydrocarbon chains having the largest number of carbon atoms (hereinafter also referred to as the longest hydrocarbon chain), the main chains are determined in the following order.
1. The side chain branching off from the longest hydrocarbon chain with the larger number of carbon atoms is considered to be the main chain.
2. Next, if the number of carbon atoms in the side chains branching off from the longest hydrocarbon chain is the same, the chain with the greater number of side chains branching off from the longest hydrocarbon chain is determined to be the main chain.
3. Next, if the number of side chains branching off from the longest hydrocarbon chain is the same, the one having a side chain on the carbon atom closer to the oxygen atom, counting from the carbon atom bonded to the oxygen atom, is determined to be the main chain.
4. Next, if the positions of the carbon atoms having side chains closest to the oxygen atom are the same, the side chain having the greater number of carbon atoms closest to the oxygen atom is determined to be the main chain.
When two or more longest hydrocarbon chains have the same symmetrical structure, either one may be the main chain.

In each of the branched alkyl groups R ^1a and R ^2a , the total number of carbon atoms constituting the side chains may be the same or different, and is preferably 3 from the viewpoint of virus inactivation performance.
In the present invention, the total number of carbon atoms constituting the side chains refers to the total number of carbon atoms in all side chains other than the main chain in one branched alkyl group, and when there are multiple side chains, it refers to the total number of carbon atoms in all of those side chains.

The number of side chains of R ^1a and R ^2a may be the same or different and is 1 or more, preferably 3 or less, more preferably 2 or less, from the viewpoint of virus inactivation performance.
In the present invention, the number of side chains refers to the number of side chains branching from the main chain, and the number of side chains does not change even if the side chain has a side chain branching from the side chain. However, from the viewpoint of improving water solubility, the side chain may have a side chain branching from the side chain.

The number of branched carbons in R ^1a and R ^2a may be the same or different, and from the viewpoint of virus inactivation performance, is 1 or more, and preferably 3 or less, and even more preferably 2 or less.
In the present invention, the number of branched carbon atoms means the total number of tertiary carbon atoms and quaternary carbon atoms in the branched chain hydrocarbon group.

In a preferred embodiment of R ^1a and R ^2a , the total carbon number of the branched chain hydrocarbon group of R ^1a and R ^2a is independently 9 or more and 12 or less, further 9 or 10, the number of carbon atoms in the main chain is independently 6 or 7, the number of carbon atoms constituting the side chain is independently 1 or more and 3 or less, and the number of side chains is independently 1.

Specific branched alkyl groups for R ^1a and R ^2a may be the same or different, and are preferably branched alkyl groups selected from a 2-propylheptyl group and a 3,5,5-trimethylhexyl group.

In formula (a1), A ¹ and A ² each independently represent an alkylene group having 2 or more carbon atoms and 4 or less, preferably 3 or less, carbon atoms.
In general formula (a1), x and y represent the average number of moles added, and from the viewpoint of virus inactivation performance, each of them independently is 0 or more and 6 or less, preferably 4 or less, more preferably 2 or less, and even more preferably 0.
Furthermore, from the viewpoint of virus inactivation performance, x+y is preferably 0 or more and preferably 12 or less, more preferably 6 or less, even more preferably 3 or less, and still more preferably 0.

In general formula (a1), ^M1 represents a hydrogen ion, or an inorganic cation such as a sodium ion, an ammonium ion, a potassium ion, or a magnesium ion, or an organic cation such as a monoethanolammonium ion, a diethanolammonium ion, a triethanolammonium ion, or a morpholinium ion, and is preferably an inorganic cation selected from the group consisting of a sodium ion, an ammonium ion, a potassium ion, and a magnesium ion.

In the general formula (a1), the preparation method of the compound in which R ^1a and R ^2a are the same is not particularly limited, but it can be prepared by referring to, for example, the method described in U.S. Patent Specification No. 2,028,091, and the preparation method of an asymmetric compound in which R ^1a and R ^2a are different can be prepared by referring to, for example, JP-A-58-24555. As the raw material of component (a), an addition product of an alkylene oxide to an alcohol having a predetermined number of carbon atoms can also be used.
Suitable alcohols for use in the production of component (a) of the present invention include:
(1) Primary alcohols such as 3,5,5-trimethylhexan-1-ol and 2-propylheptan-1-ol,
(2) Secondary alcohols such as 5-nonanol and 2,6-dimethyl-4-heptanol.

The SARS-coronavirus 2 inactivating agent of the present invention contains component (a) as an active ingredient.
From the viewpoint of virus inactivation performance, the SARS coronavirus 2 inactivator of the present invention contains component (a) in an amount of preferably 0.001% by mass or more, more preferably 0.01% by mass or more, even 0.1% by mass or more, even 0.3% by mass or more, even 1% by mass or more, even 5% by mass or more, even 10% by mass or more, even 25% by mass or more, even 50% by mass or more, even 75% by mass or more, even 90% by mass or more, and preferably 100% by mass or less.
The SARS-coronavirus 2 inactivating agent of the present invention may contain 100% by mass of the component (a). That is, the present invention may be a SARS-coronavirus 2 inactivating agent consisting of the component (a).
In the present invention, the mass of component (a) is defined as a value converted into a sodium salt.

The SARS-coronavirus 2 inactivating agent of the present invention may contain other components besides component (a) to the extent that the effect of the present invention is not impaired.
Other ingredients include water, surfactants, solvents, preservatives, colorants, fragrances, defoamers, sequestering agents, stabilizers, pH adjusters, etc.

SARS-CoV-2, which is the target of the coronavirus inactivator of the present invention, is a SARS-associated coronavirus that causes acute respiratory disease (COVID-19). SARS-CoV-2 has a viral genome of about 29,903 bases and is a single-stranded positive-strand RNA virus. The virus particles (virions) are about 50-200 nm in size. Like common coronaviruses, it is composed of four proteins known as spike protein, nucleoprotein, integral membrane protein, and envelope protein, as well as RNA. Of these, the nucleoprotein binds to RNA to form the nucleocapsid, and the spike protein bound to lipids, the integral membrane protein, and the envelope protein surround it to form an envelope (Apneumonia outbreak associated with a new coronavirus of probable batorigin. Nature. 2020 Mar; 579 (7798): 270-273., A new coronavirus associated with human respiratory disease in China. Nature. 2020 Mar; 579 (7798): 265-269.)

The spike protein is a large type I transmembrane protein consisting of two subunits, S1 and S2. S1 mainly contains the receptor binding domain (RBD) that recognizes receptors on the cell surface, while S2 contains elements necessary for membrane fusion. Known receptors that bind to S1 include ACE2 (angiotensin-converting enzyme 2), DPP4 (dipeptidyl peptidase-4), APN (aminopeptidase N), CEACAM (carcinoembryonic antigen-related cell adhesion molecule 1), and O-acSia (O-acetylated sialic acid). SARS-CoV-2 has been reported to infect human respiratory epithelial cells via human ACE2 (Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein Cell. Volume 181, Issue 2, 16 April 2020, Pages 281-292. e6)

SARS-CoV-2 was first identified in 2019 near Wuhan, Hubei Province, China, and has since caused the COVID-19 pandemic, making it a very challenging virus.

The present invention provides the use of the component (a) as an SARS coronavirus 2 inactivating agent containing the component (a) as an active ingredient.
The component (a) is the same as that described in the SARS-coronavirus 2 inactivating agent of the present invention.
For use as the SARS-coronavirus 2 inactivating agent of the present invention, the embodiments described for the SARS-coronavirus 2 inactivating agent of the present invention can be appropriately applied.

[Composition for inactivating SARS coronavirus 2]
The present invention provides a composition for inactivating SARS-coronavirus 2, which contains component (a) as an active ingredient and also contains water.
In the present invention, a method of contacting a composition for inactivating SARS-coronavirus 2 containing component (a) and water with SARS-coronavirus 2 or with a target surface on which SARS-coronavirus 2 is present is preferred from the standpoints of simplicity and inactivation effect.
The component (a) is the same as that described in the SARS-coronavirus 2 inactivating agent of the present invention.
The composition for inactivating SARS-coronavirus 2 of the present invention may be prepared by blending the SARS-coronavirus 2 inactivator of the present invention. That is, the present invention may be a composition for inactivating SARS-coronavirus 2 that contains the SARS-coronavirus 2 inactivator of the present invention as an active ingredient and also contains water.
The composition for inactivating SARS-coronavirus 2 of the present invention can appropriately adopt the aspects described for the SARS-coronavirus 2 inactivating agent of the present invention.

The SARS coronavirus 2 inactivating composition of the present invention contains component (a) at a concentration of preferably 10 ppm by mass or more, more preferably 20 ppm by mass or more, even more preferably 30 ppm by mass or more, and even more preferably 50 ppm by mass or more from the viewpoint of virus inactivation performance, and preferably 30,000 ppm by mass or less, more preferably 20,000 ppm by mass or less, even more preferably 10,000 ppm by mass or less, even more preferably 1000 ppm by mass or less, even more preferably 500 ppm by mass or less, even more preferably 250 ppm by mass or less, and even more preferably 100 ppm by mass or less from the viewpoint of blend stability. The SARS coronavirus 2 inactivating composition of the present invention is preferable in that it can inactivate the virus in a short time even at a low concentration of component (a), preferably 10 ppm by mass or more and 250 ppm by mass or less, and more preferably 10 ppm by mass or more and 100 ppm by mass or less.

The composition for inactivating SARS-coronavirus 2 of the present invention contains water. That is, the remainder of the composition for inactivating SARS-coronavirus 2 of the present invention other than component (a) and the optional components described below is water.
The composition for inactivating SARS-coronavirus 2 of the present invention contains water in an amount of preferably more than 40% by mass, more preferably more than 45% by mass, even more preferably more than 50% by mass, particularly preferably more than 60% by mass, and preferably less than 99.99% by mass, more preferably less than 99.9% by mass, even more preferably less than 99.7% by mass, still more preferably less than 98% by mass, and particularly preferably less than 96% by mass.

When the SARS-coronavirus 2 inactivation composition of the present invention is used in a method of contacting the composition with an object, it may contain (b) a surfactant (excluding component (a)) [hereinafter referred to as component (b)] in terms of wettability and permeability to the object, and removability of adhering dirt.

Examples of the (b) component include one or more selected from (b1) semi-polar surfactants (hereinafter referred to as (b1) component), (b2) amphoteric surfactants (hereinafter referred to as (b2) component), (b3) anionic surfactants (excluding (a) component) (hereinafter referred to as (b3) component), and (b4) nonionic surfactants (hereinafter referred to as (b4) component).

Examples of the component (b1) include amine oxide surfactants having one or more alkyl groups, preferably one, having 8 to 22 carbon atoms.
Examples of the component (b2) include sulfobetaine surfactants having one or more, preferably one, alkyl group having 8 to 22 carbon atoms, and carbobetaine surfactants having one or more, preferably one, alkyl group having 8 to 22 carbon atoms.
Examples of the component (b3) include one or more selected from alkyl sulfates having an alkyl group with 8 to 22 carbon atoms, alkylbenzene sulfonic acids having an alkyl group with 8 to 22 carbon atoms, polyoxyalkylene alkyl ether sulfates having an alkyl group with 8 to 22 carbon atoms (the oxyalkylene group is an oxyalkylene group having 2 or 3 carbon atoms, preferably an oxyethylene group, and the average number of moles added of the oxyalkylene group is 0.5 to 5, preferably 0.5 to 3), fatty acids having 8 to 14 carbon atoms, and salts thereof.
Examples of the component (b4) include one or more selected from polyoxyalkylene alkyl ethers having an alkyl group with 8 to 22 carbon atoms (the oxyalkylene group is an oxyalkylene group having 2 or 3 carbon atoms, preferably an oxyethylene group, and the average number of moles of the oxyalkylene group added is 3 to 50, preferably 3 to 20), and alkyl glycosides having an alkyl group with 8 to 22 carbon atoms (the average degree of condensation of the sugar skeleton, such as glucose, is 1 to 5, preferably 1 to 2).

The composition for inactivating SARS-coronavirus 2 of the present invention contains component (b) in an amount of preferably 0.01% by mass or more, more preferably 0.05% by mass or more, even more preferably 0.1% by mass or more, and preferably 50% by mass or less, more preferably 40% by mass or less, even more preferably 20% by mass or less, from the viewpoints of wettability and permeability to the target object, and removability of adhered dirt.
In the present invention, when component (b3) is used as component (b), the mass of component (b3) is defined as a value converted into a sodium salt.

When the composition for inactivating SARS-coronavirus 2 of the present invention contains component (b), the mass ratio (a)/(b) of the content of component (a) to the content of component (b) is preferably 0.01 or more, more preferably 0.05 or more, even more preferably 0.1 or more, even more preferably 0.2 or more, and preferably 15 or less, more preferably 10 or less, and even more preferably 5 or less, from the viewpoint of virus inactivation performance and removability of adhering dirt.

The composition for inactivating SARS-coronavirus 2 of the present invention may contain (c) a water-soluble organic solvent (hereinafter referred to as component (c)) in terms of wettability and permeability to the target object.
The water-soluble organic solvent of the present invention is one that dissolves in an amount of 20 g or more in 100 g of deionized water at 20°C.

The (c) component may be one or more selected from (c1) polyhydric alcohols having 2 to 4 carbon atoms, (c2) di- or tri-alkylene glycols having 2 to 4 carbon atoms in the alkylene glycol unit, and (c3) monoalkoxy (methoxy, ethoxy, propoxy, butoxy) ethers, phenoxy, or benzooxy ethers of di- or tetra-alkylene glycols having 2 to 4 carbon atoms in the alkylene glycol unit.

The component (c) is preferably a water-soluble organic solvent having 2 or more carbon atoms, preferably 3 or more carbon atoms, and 12 or less carbon atoms, preferably 8 or less carbon atoms.
Specifically, (c1) includes ethylene glycol, propylene glycol, glycerin, and isoprene glycol, (c2) includes diethylene glycol and dipropylene glycol, and (c3) includes propylene glycol monomethyl ether, propylene glycol monoethyl ether, diethylene glycol monobutyl ether (also called butyl diglycol, etc.), dipropylene glycol monobutyl ether, phenoxyethanol, phenoxytriethylene glycol, and phenoxyisopropanol, and these can be used alone or in combination. As the (c) component, one or more water-soluble organic solvents selected from propylene glycol, dipropylene glycol, diethylene glycol monobutyl ether, phenoxyethanol, phenyl glycol, and phenoxyisopropanol are preferred. As the (c) component, those having an alkoxy group are preferred, and diethylene glycol monobutyl ether is more preferred.

In addition, monohydric alcohols having 1 to 3 carbon atoms, which are water-soluble organic solvents [hereinafter referred to as component (c4)], are used as sterilizing and disinfecting alcohols, and a sterilizing effect can be obtained by including them in high concentrations. However, it is desirable to ensure mildness in the formulation so that they can be used in products that frequently come into contact with the human body, such as the skin.

The content of component (c4) in the composition for inactivating SARS coronavirus 2 of the present invention is preferably 50% by mass or less, more preferably 30% by mass or less, even more preferably 10% by mass or less, even more preferably 5% by mass or less, even more preferably 1% by mass or less, even more preferably 0.5% by mass or less, and even more preferably 0.1% by mass or less, from the viewpoint of skin irritation. In addition, the composition for inactivating SARS coronavirus 2 of the present invention does not need to contain an alcohol having 1 to 3 carbon atoms.

The composition for inactivating SARS coronavirus 2 of the present invention can contain component (c) (excluding component (c4)), particularly components (c1) to (c3), preferably at 0.001% by mass or more, more preferably at 0.01% by mass or more, even more preferably at 0.03% by mass or more, even more preferably at 0.05% by mass or more, even more preferably at 0.1% by mass or more, and preferably at 50% by mass or less, more preferably at 30% by mass, even more preferably at 20% by mass or less, and even more preferably at 15% by mass or less.

The composition for inactivating SARS coronavirus 2 of the present invention has a high inactivation effect against SARS coronavirus 2 even without containing a bactericide.
Specific examples of disinfectants include quaternary ammonium salt compounds such as benzalkonium chloride, benzalkonium alkyl phosphate, benzethonium chloride, and cetylpyridinium chloride; and one or more selected from triclosan, isopropylmethylphenol, resorcinol, trichlorocarbanide, chlorhexidine chloride, chlorhexidine gluconate, hydrogen peroxide, povidone-iodine, and tincture of iodine.

The SARS-coronavirus 2 inactivating composition of the present invention should be used with care because the SARS-coronavirus 2 inactivating effect of the present invention may be reduced if it contains a bactericide other than component (a), particularly a cationic bactericide. The bactericide content of the SARS-coronavirus 2 inactivating composition of the present invention is preferably 5% by mass or less, more preferably 1% by mass or less, even more preferably 0.1% by mass or less, and even more preferably 0.01% by mass or less. However, component (a) is excluded from the bactericide. The SARS-coronavirus 2 inactivating composition of the present invention does not have to contain a bactericide.

The composition for inactivating SARS-coronavirus 2 of the present invention can contain ingredients such as inorganic salts, inorganic acids, chelating agents, fragrances (natural fragrances, synthetic fragrances), thickeners, gelling agents, polymeric compounds (dispersants), hydrotropes, moisturizers, preservatives, antioxidants, light stabilizers, antiseptics, buffers, and defoamers, to the extent that the effects of the present invention are not impaired.

The composition for inactivating SARS coronavirus 2 of the present invention has a high inactivation effect on SARS coronavirus 2 even when the pH is in the acidic to alkaline range.
In the composition for inactivating SARS coronavirus 2 of the present invention, the pH at 25°C measured by a glass electrode method can be selected from 0 or more, further 1 or more, further 2 or more, further 3 or more, further 4 or more, further 5 or more, and 13 or less, further 12 or less, further 11 or less, further 10 or less, and further 9 or less, from the viewpoint of skin irritation.

The SARS-coronavirus 2 inactivating composition of the present invention can be used, for example, in the form of a liquid, gel, or paste. Depending on the form of use, the SARS-coronavirus 2 inactivating composition of the present invention, water, a solubilizing carrier such as a solvent, a gelling agent, etc. can be appropriately contained.

The target surfaces on which the composition for inactivating SARS-coronavirus 2 of the present invention is used include (1) the body, such as human skin, fingers, hair, and the inside of the mouth, (2) food, such as the surfaces of food materials such as vegetables, (3) hard objects, and (4) textile products, such as textile materials such as cloth and thread, and products manufactured using these. Examples of hard objects include hard objects having a hard surface, such as bathrooms, toilets, kitchens, floors, doorknobs, tableware, food processing equipment, desks, chairs, and walls. These hard objects may be used at home or in public facilities or factories, such as swimming pools, bathhouses, cafeterias, and hospitals.

The SARS coronavirus 2 targeted by the SARS coronavirus 2 inactivation composition of the present invention is the same as the SARS coronavirus 2 listed as the SARS coronavirus 2 inactivator of the present invention.

<Method of inactivating SARS coronavirus 2>
The present invention provides a method for inactivating SARS-coronavirus 2, which comprises contacting a target surface on which SARS-coronavirus 2 is present with the SARS-coronavirus 2 inactivating composition of the present invention or a treatment liquid obtained by diluting the composition with water.
The embodiment in which the SARS-coronavirus 2 inactivating composition of the present invention is brought into contact with the target surface may be such that the SARS-coronavirus 2 inactivating composition of the present invention is brought into contact with the target surface in its original form without diluting it with water, or the SARS-coronavirus 2 inactivating composition of the present invention may be brought into contact with the target surface as a treatment liquid obtained by diluting it with water.
When preparing a treatment solution by diluting the SARS-coronavirus 2 inactivating composition of the present invention with water, the dilution ratio is preferably 1,000-fold or less, more preferably 500-fold or less, even more preferably 100-fold or less, and even more preferably 50-fold or less, from the viewpoint of virus inactivation performance. Alternatively, the SARS-coronavirus 2 inactivating composition of the present invention may be used as an undiluted solution.

For the method of inactivating SARS-coronavirus 2, the embodiments described for the SARS-coronavirus 2 inactivating agent of the present invention and the composition for inactivating SARS-coronavirus 2 of the present invention can be appropriately applied.
The target surfaces are the same as those listed in the composition for inactivating SARS coronavirus 2 of the present invention.

There is no particular limitation on the form of use when the SARS-coronavirus 2 inactivating composition of the present invention or a treatment liquid obtained by diluting the composition with water is brought into contact with a hard surface on which SARS-coronavirus 2 is present, but the SARS-coronavirus 2 inactivating composition of the present invention or a treatment liquid obtained by diluting the composition with water can be used as a spray, lotion, etc. For example, the composition can be filled into a known spray container such as a trigger spray container (direct pressure or pressure accumulation type) or a dispenser-type pump spray container, and the spray amount can be adjusted so that it can be sprayed on a target surface on which SARS-coronavirus 2 is present or is thought to be present.
It can also be used as a wet wipe (wet napkin, etc.). For example, the composition for inactivating SARS-coronavirus 2 of the present invention or a treatment solution obtained by diluting the composition with water, a solubilizing carrier, and various additives as necessary can be added to a substrate containing a woven or nonwoven web of natural fibers, regenerated fibers such as rayon, synthetic fibers such as polyethylene, polypropylene, polyester, or a mixture of natural and synthetic fibers. Specifically, it can be used for skin conditioners, pet care products, surfaces of home kitchens, bathrooms, toilets, toilet seats, etc., surfaces of exercise equipment, etc.

When the SARS coronavirus 2 inactivation composition of the present invention or a treatment liquid obtained by diluting it with water is made into a gel or paste using a water-soluble or oil-based gel, it can be used as a medical product by directly applying it to the human body, pets, etc., or it can be supported on paper, nonwoven fabric, etc. and used as a filter for an air purifier or air conditioner.

The amount of the SARS-coronavirus 2 inactivating composition of the present invention or a treatment solution obtained by diluting the composition with water to be used is not particularly limited. For example, the amount of component (a) per unit area of ¹ m2 of an object can be preferably 0.01 mg or more, more preferably 0.1 mg or more, and preferably 1,000 mg or less, more preferably 500 mg or less, from the viewpoints of virus inactivation performance and finish after use.

The time for which the SARS coronavirus 2 inactivation composition of the present invention or a treatment solution obtained by diluting it with water is brought into contact with a target surface on which SARS coronavirus 2 is present (time for which it is left standing) is, from the viewpoint of virus inactivation performance, preferably 15 seconds or more, more preferably 30 seconds or more, even more preferably 1 minute or more, and preferably 2 hours or less, more preferably 1 hour or less, even more preferably 30 minutes or less, even more preferably 10 minutes or less, even more preferably 5 minutes or less, even more preferably 3 minutes or less, and even more preferably 1 minute or less.

Examples 1 to 4, Comparative Examples 1 to 3
[Anti-SARS-CoV-2 validation test using VeroC1008]
The outline of the anti-SARS-CoV-2 validation test using VeroC1008 is as follows.

(material)
SARS-CoV-2: JPN/TY/WK-521
Cell: Vero C1008 (ATCC CRL-1586)
Culture medium: 500mL MEM (Sigma-Aldrich, M4655)
5mL Penicillin-Streptomycin (10,000 U/mL) (Gibco, 15140122)
FBS：biosera,FB-1365/500,Lot10259
Inactivation: 56℃, 30 minutes. Add to 10% medium during normal culture. Add to 2% medium during infection.
Trypsin: TrypLE® Select Enzyme (1X), no phenol red (Gibco, 12563011)
RT-qPCR: SARS-CoV-2 Detection Kit-N2 set-(Toyobo, NCV-302)

(protocol)
1. VeroC1008 was seeded onto a 96-well plate so that it became 100% confluent.
2. Component (a) or component (a') (a comparative component for component (a)) was diluted with autoclaved tap water to prepare the evaluation liquids shown in Table 1.
3. 27 μL of the evaluation solution and 3 μL of SARS-CoV-2 solution (equivalent to approximately 4 × 10 ⁵ TCID ₅₀ ) were mixed.
4. The reaction was allowed to proceed at room temperature for 10 minutes.
The reaction was stopped by adding 270 μL of 5.2% FBS medium.
20 μL of the solution in 6.5 was added to a 96 well plate of Vero C1008 whose medium had been replaced with 180 μL of 2% FBS medium in advance, and mixed.
7. Infection was carried out for 1 hour at 37°C/5% _CO2 .
The plate was washed twice with 200 μL of 8.2% FBS medium.
9. The cells were cultured at 37°C/5% _CO2 for 3 days.
10. SARS-CoV-2 inactivation was determined by viral cytopathic effect and RT-qPCR.
SARS-CoV-2 was deemed to have been inactivated when no cytopathic effect due to the virus was observed under a microscope using an IX73 (Olympus Corporation) and the viral genome was not detectable by RT-qPCR of the culture supernatant. The virus was deemed to have proliferated when the Ct (Threshold Cycle) value in RT-qPCR was less than 30.

[Test Results]
The results are shown in Table 1. Products that showed inactivation of SARS-CoV-2 in the anti-SARS-CoV-2 validation test using Vero C1008 were marked with "◯", and products that did not show inactivation of SARS-CoV-2 were marked with "×".

<Method for producing sodium di-(2-propylheptyl)sulfosuccinate>
The sodium di-(2-propylheptyl)sulfosuccinate listed in Table 1 was prepared as follows. 176.5 g (1.8 mol) of maleic anhydride, 626.6 g (4.0 mol) of 2-propylheptanol, and 2.5 g (0.013 mol) of p-toluenesulfonic acid monohydrate were charged into a 2 L four-neck flask equipped with a stirrer, a heating system, a distillation column, and a nitrogen/vacuum connection, and after nitrogen replacement, the mixture was reacted under nitrogen bubbling at 100 to 130° C. while dehydrating until the acid value was reduced to the amount equivalent to p-toluenesulfonic acid. The catalyst was then adsorbed using Kyoward 500SH (manufactured by Kyowa Chemical Industry Co., Ltd.) in an amount of 1% by mass relative to the total amount of the reaction vessel contents. After removing the adsorbent, the excess alcohol was removed by topping to obtain a maleic acid diester.

Next, 278 g (0.70 mol) of the maleic acid diester obtained above, 73 g (0.38 mol) of sodium disulfite, and 48 g (2.7 mol) of ion-exchanged water were charged into a 1 L glass reaction vessel, and the mixture was reacted at 115°C using an alcohol-based polar solvent by a known method until the double bond derived from the maleic acid diester disappeared by NMR. The mixture was cooled to 50 to 65°C, and the remaining sodium hydrogen sulfite was oxidized with 30% hydrogen peroxide, and then the pH was adjusted to 5 with 10% NaOH. The solvent and sodium sulfate were removed by distillation under reduced pressure, reprecipitation, separation, etc., to obtain sodium di-(2-propylheptyl)sulfosuccinate. The following components were used in the production of sodium di-(2-propylheptyl)sulfosuccinate.
Maleic anhydride: FUJIFILM Wako Pure Chemical Industries, Ltd., Wako special grade 2-Propylheptanol: FUJIFILM Wako Pure Chemical Industries, Ltd., Reagent special grade p-Toluenesulfonic acid monohydrate: FUJIFILM Wako Pure Chemical Industries, Ltd., Reagent special grade Sodium disulfite: FUJIFILM Wako Pure Chemical Industries, Ltd., Reagent special grade

Claims (8)

(a) A SARS coronavirus 2 inactivator containing, as an active ingredient, a branched alkyl sulfosuccinate ester having a branched alkyl group having 9 to 12 carbon atoms or a salt thereof (hereinafter referred to as ingredient (a)). The SARS-coronavirus 2 inactivating agent according to claim 1, wherein component (a) is a branched alkyl sulfosuccinate ester having a branched alkyl group of 9 or 10 carbons or a salt thereof. The SARS coronavirus 2 inactivator according to claim 1 or 2, containing 0.001% by mass or more and 100% by mass or less of component (a). (a) A composition for inactivating SARS coronavirus 2, which contains as an active ingredient a branched alkyl ester of sulfosuccinic acid having a branched alkyl group having 9 to 12 carbon atoms or a salt thereof (hereinafter referred to as ingredient (a)) and contains water. The composition for inactivating SARS-coronavirus 2 according to claim 4, wherein component (a) is a branched alkyl sulfosuccinate ester having a branched alkyl group of 9 or 10 carbons or a salt thereof. The composition for inactivating SARS-coronavirus 2 according to claim 4 or 5, containing component (a) in an amount of 10 ppm by mass or more and 30,000 ppm by mass or less. A method for inactivating SARS-coronavirus 2 (excluding medical procedures for humans), comprising contacting a target surface on which SARS-coronavirus 2 is present with the composition for inactivating SARS-coronavirus 2 according to any one of claims 4 to 6 or a treatment liquid obtained by diluting the composition with water. The method for inactivating SARS-coronavirus 2 according to claim 7, wherein the SARS-coronavirus 2 inactivation composition or a treatment solution obtained by diluting the composition with water is brought into contact with a target surface on which SARS-coronavirus 2 is present for 1 minute or more and 30 minutes or less.